Stay updated with breaking news from After First Line. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
NSCLC Atalante-1 Phase 3 Trial Beyond Checkpoint Inhibitor Neoepitope Specific Immunotherapy Tedopi® Shows Significant Patient-Reported Outcomes Versus ChemotherapyPositive Interim Results in... | June 7, 2022
23.05.2022 - Regulatory News: OSE Immunotherapeutics SA (Paris:OSE) (ISIN: FR0012127173; Mnemo: OSE) and its clinical partners GERCOR, ARCAGY-GINECO and the FoRT Foundation (Fondazione Ricerca Traslazionale), today announced four poster presentations* featuring ... Seite 1